Novartis Licenses Preclinical Radioligand Asset From BoomRay
Suzhou-based BoomRay granted Novartis exclusive global rights to an undisclosed preclinical radioligand therapy asset. BoomRay is eligible for up to $900 million including upfront, development, regulatory, and sales payments, plus royalties. The transaction is…
